SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Catheter Precision, Inc. (VTAK) (CIK 0001716621) (VJET) — Feb 25, 2020

Catheter Precision, Inc. (VTAK) (CIK 0001716621)
Date: Feb. 25, 2020 · CIK: 0001716621 · Accession: 0000000000-20-001689

AI Filing Summary & Sentiment

File numbers found in text: 001-38677

Date
February 24, 2020
Author
Not clearly detected
Form
UPLOAD
Company
Catheter Precision, Inc. (VTAK) (CIK 0001716621)

Letter

February 24, 2020 Andrew Jackson Chief Financial Officer Ra Medical Systems, Inc. 2070 Las Palmas Drive Carlsbad, CA 92011 Re:Ra Medical Systems, Inc. Form 10-K For the Fiscal Year Ended December 31, 2018 Filed March 15, 2019 File No. 001-38677 Dear Mr. Jackson: Consistent with our obligations under the federal securities laws, we are terminating our review and will take further steps as we deem appropriate. These steps include releasing publicly, through the agency’s EDGAR system, all correspondence, including this letter, relating to the review of your filing, consistent with the staff’s decision to publicly release comment and response letters relating to disclosure filings it has reviewed. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text
February 24, 2020
Andrew Jackson
Chief Financial Officer
Ra Medical Systems, Inc.
2070 Las Palmas Drive
Carlsbad, CA 92011
Re:Ra Medical Systems, Inc.
Form 10-K For the Fiscal Year Ended December 31, 2018
Filed March 15, 2019
File No. 001-38677
Dear Mr. Jackson:
            Consistent with our obligations under the federal securities laws, we are terminating our
review and will take further steps as we deem appropriate. These steps include releasing
publicly, through the agency’s EDGAR system, all correspondence, including this letter, relating
to the review of your filing, consistent with the staff’s decision to publicly release comment and
response letters relating to disclosure filings it has reviewed.
Sincerely,
Division of Corporation Finance
Office of Life Sciences